DrugPatentWatch Database Preview
Pegfilgrastim - Biologic Drug Details
» See Plans and Pricing
Summary for pegfilgrastim
Tradenames: | 1 |
Patents: | 99 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 1 |
Recent Clinical Trials: | See clinical trials for pegfilgrastim |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for pegfilgrastim |
Recent Clinical Trials for pegfilgrastim
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Dana-Farber Cancer Institute | Phase 1 |
Qilu Pharmaceutical Co., Ltd. | Phase 1 |
University of Washington | Phase 1/Phase 2 |
Pharmacology for pegfilgrastim
Ingredient-type | Granulocyte Colony-Stimulating Factor Granulocyte-Macrophage Colony-Stimulating Factor |
Physiological Effect | Increased Myeloid Cell Production |
Company Disclosures: US Patents for pegfilgrastim
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2013-12-03 | RX | Orphan | company |
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2013-12-10 | RX | Orphan | company |
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2039-02-26 | RX | Orphan | company |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for pegfilgrastim
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Intezyne Technologies, Inc. (Tampa, FL) | 2025-04-01 | RX | Orphan | search |
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Bayer Healthcare LLC (Tarrytown, NY) | 2024-04-30 | RX | Orphan | search |
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Yale University (New Haven, CT) | 2025-06-07 | RX | Orphan | search |
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Yale University (New Haven, CT) | 2025-12-02 | RX | Orphan | search |
Amgen | NEULASTA | pegfilgrastim | SYRINGE | 125031 | 001 | 2002-01-31 | Start Trial | Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A) | 2026-02-17 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for pegfilgrastim
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 108969767 | Start Trial |
Bulgaria | 60170 | Start Trial |
Poland | 1976532 | Start Trial |
Russian Federation | 2015125706 | Start Trial |
Germany | 602006008625 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for pegfilgrastim
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
C0006 | France | Start Trial | PRODUCT NAME: LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130729 |
C/GB14/009 | United Kingdom | Start Trial | PRODUCT NAME: LIPEGFILGRASTIM; REGISTERED: UK EU/1/13/856/001 20130729 |
02C/040 | Belgium | Start Trial | PRODUCT NAME: PEGFILGRASTIM; AUTHORISATION NUMBER AND DATE: EU/1/02/227/001 20020823 |
358 | Luxembourg | Start Trial | PRODUCT NAME: LIPEGFILGRASTIM |
5/2003 | Austria | Start Trial | PRODUCT NAME: PEGFILGRASTIM |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |